Eli Lilly Q1 Non-GAAP Earnings, Revenue Rise; 2025 Earnings Guidance Trimmed
Express News | Eli Lilly : Leerink Partners Cuts Target Price to $944 From $989
TD Cowen Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,050
Top Gap Ups and Downs on Thursday: MSFT, LLY, QCOM and More
Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk
What happened? Eli Lilly and Co's Q1 revenue surged by 45%, but the stock price plummeted more than 10% during trading.
In the first quarter, Eli Lilly and Co's weight loss drug Zepbound saw sales increase more than threefold, while the annual EPS guidance was lowered by over 7% due to acquisition-related expenses, with the annual revenue guidance remaining unchanged, but only reflecting the impact of Trump tariffs as of early May. The chain pharmacy giant CVX has decided to include Novo-Nordisk A/S's Wegovy as the preferred option in its main prescription drug catalog starting in July, while Zepbound was not included, with the CEO of Eli Lilly and Co calling it "a step backward."
Eli Lilly and Co Options Spot-On: On May 1st, 154.69K Contracts Were Traded, With 294.3K Open Interest
US Equities Markets End Higher Thursday as Investors Await Apple, Amazon Results
Sector Update: Health Care Stocks Slide Late Afternoon
Is Eli Lilly and Company (LLY) the Best Growth Stock to Buy for the Next 3 Years?
Why Eli Lilly (LLY) Stock Is Nosediving
WHO Set to Back Use of Weight Loss Drugs Such as Zepbound, Wegovy - Report
Earnings Call Summary | Eli Lilly and Co(LLY.US) Q1 2025 Earnings Conference
Wall Street Eyes 8th Positive Day As S&P 500 Recoups Tariff-Led Losses, Bitcoin Rallies To $97,000: What's Driving Markets Thursday?
8 Health Care Stocks Whale Activity In Today's Session
Research Alert: CFRA Keeps Buy Opinion On Shares Of Eli Lilly And Company
Eli Lilly Down Over 10%, on Pace for Largest Percent Decrease Since October 2008 -- Data Talk
Trending Stocks Today | Zoomcar Holdings Soars 246.43%
30 U.S. Picks Based on Up Vs. Down EPS Revisions and Dividend Payouts
Top Midday Stories: Microsoft, Meta Earnings Top Estimates; Eli Lilly Cuts Guidance Despite Strong Q1 Earnings